A Word from AST President & CEO Joe Hoff It’s common practice at AST to revisit our Mission Statement as we go about our work to provide quality fill-finish solutions to our customers. That mission—to enhance the reliability, productivity and safety of aseptic processing by offering intelligent, intuitive, and innovative solutions—informs every aspect of what […]

For small-batch, high-value drug products, the aseptic advantages of pre-sterilized ready-to-use vials are clear.  To realize the full scope of benefits that RTU vials can provide, integration with traditional processes and equipment must be carefully considered.  Modern and flexible technologies such as robotics are key to seamlessly integrating RTU vials into aseptic fill/finish processes. The […]

Throughout the lifecycle of a drug product, many critical target points for optimization make all the difference in the time-to-market equation. A holistic approach to the drug development process that’s able to anticipate challenges in production, regulatory requirements, and manufacturing practices should be considered. A key component of this approach is establishing early and clear […]

Small-batch manufacturing of liquid pharmaceuticals is slated for exponential growth in the coming years and represents exciting possibilities for the future of medicine and personalized healthcare. Whether biologics, biosimilars, or orphan drugs developed in the fight against rare diseases, technology is providing solutions for the manufacturing challenges traditionally associated with small-batch aseptic processing and consequently […]

Revolutionary Collaboration to Introduce an American-Made Turn-Key Solution with Unparalleled Innovation Ormond Beach, Florida, and Tacoma, Washington, 09-October-2023 — Germfree Laboratories, a global leader in isolator technology for aseptic processing and containment in the pharmaceutical sector, and AST, a pioneer in aseptic fill-finish processing technology, are thrilled to announce a revolutionary partnership. This landmark collaboration […]

The last four years have seen remarkable developments in the field of cell and gene therapy. In 2019, the FDA forecasted that the US is likely to add 10-20 cell and gene therapies per year until 2025, and current prognostication has development tracking at that speed.

The last four years have seen remarkable developments in the field of cell and gene therapy. In 2019, the FDA forecasted that the US is likely to add 10-20 cell and gene therapies per year until 2025, and current prognostication has development tracking at that speed.

The last four years have seen remarkable developments in the field of cell and gene therapy. In 2019, the FDA forecasted that the US is likely to add 10-20 cell and gene therapies per year until 2025, and current prognostication has development tracking at that speed.

When deciding on an aseptic fill/finish machine, the choice to use a gloved or gloveless isolator will arise – and we want to help with that decision. There are a few attributes to consider when choosing between a gloved or a gloveless isolator.

When deciding on an aseptic fill/finish machine, the choice to use a gloved or gloveless isolator will arise – and we want to help with that decision. There are a few attributes to consider when choosing between a gloved or a gloveless isolator.